Opportunity
Quebec SEAO #AE-AI-20260427
Sole-source procurement of NETSPOT kits for Gallium-68 PET imaging by CISSS des Laurentides
Posted
April 27, 2026
Respond By
May 09, 2026
Identifier
AE-AI-20260427
NAICS
325413
This opportunity involves the sole-source procurement of NETSPOT kits for Gallium-68 PET imaging by the Centre intégré de santé et de services sociaux (CISSS) des Laurentides in Quebec. - Government Buyer: - Centre intégré de santé et de services sociaux (CISSS) des Laurentides, a Quebec provincial health authority - OEMs and Vendors: - Novartis Pharma Canada Inc. (OEM and sole supplier) - Products/Services Requested: - NETSPOT kits: sterile, multi-dose kits containing 40 µg lyophilized oxodotreotide - Designed for Gallium-68 radiolabeling in PET imaging of neuroendocrine tumors - Must be compatible with authorized 68Ge/68Ga generators (e.g., GalliaPharm, Galli Eo) - Each kit allows up to 11 punctures - Must meet radiochimical purity ≥ 95%, be sterile, clear, pH 3.2-3.8, and usable within 4 hours post-radiolabeling - Health Canada approval required - Unique/Notable Requirements: - Only Health Canada-approved product accepted - No alternative solutions available in Canada - Strict compatibility and quality control standards - Contract Details: - Two-year contract duration - Delivery and use in the Laurentides region, Quebec
Description
The contract involves acquiring a sterile, multi-dose kit of 40 µg of lyophilized oxodotreotide for Gallium-68 radiolabeling, used in PET imaging for neuroendocrine tumors. The product must be compatible with authorized 68Ge/68Ga generators, provide a multi-dose kit with a maximum of 11 punctures, and meet quality control standards including radiochimical purity of at least 95%. The solution must be sterile, clear, have a pH between 3.2 and 3.8, be usable within 4 hours post-radiolabeling, and be approved by Health Canada. The contract is intended to be awarded as a sole-source to Novartis Pharma Canada Inc. due to the unique compliance of the NETSPOT product with technical and clinical requirements and the absence of suitable alternatives.